ExploRNA Therapeutics

Dominika Nowis, MD, PhD

ExploRNA Therapeutics
  • ExploRNA Therapeutics combines 20+ years of academic experience with exceptional industrial skills to develop novel, game-changing mRNA 5′ cap modifications that improve performance of therapeutic mRNAs.
  • Our technology is suitable for co-transcriptional capping of mRNA, enables increased translation efficiency while decreasing decapping, and improves mRNA purification process due to proprietary cap modifications.
  • ExploRNA’s portfolio includes a vast library of cap analogs and a few drug discovery programs in the pipeline.
  • We are ready to deliver our solutions, develop caps tailored to specific needs and we are pursuing new joint therapeutics programs.

Dedicated to advancing and advocating for mRNA and next generation encoding RNA therapeutics and vaccines.